Abstract

A REVIEW ON LOBEGLITAZONE AND ITS THERAPEUTIC BENEFITS

Avi Shah*, Pavan Patel, Faizan Khoraziya, Jignesh Parmar, Dr. Khushbu Patel and Dr. C. N. Patel

ABSTRACT

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the Thiazolidinediones (TZDs) primarily target insulin resistance. Thiazolidinediones improve insulin sensitivity by activating per-oxisome proliferator-activated receptor γ. Lobeglitazone is a newer oral hypoglycemic agent that has been tested in Type 2 diabetes mellitus (T2DM). We aim to conduct a narrative review to find out the therapeutic benefits of Lobeglitazone in patients with Type 2 diabetes mellitus. We retrieved all available results of phase 1 to phase 3 studies of Lobeglitazone in Type 2 diabetes mellitus. Subsequently, we reviewed the results narratively. Lobeglitazone exhibits as much antidiabetic activity as other Thiazolidinediones such as Pioglitazone and Rosiglitazone. Side effects of Lobeglitazone included peripheraledema, weight gain, and bone mineral density, which did not require hospitalization for these effects. This article highlights the pharmacological, pre-clinical, clinical, and safety pharmacology of novel Thiazolidinedione Lobeglitazone.

Keywords: Type 2 diabetes mellitus (T2DM), Thiazolidinediones (TZDs), Lobeglitazone.